Primary Central Nervous System Post-Transplantation Lymphoproliferative Disorder An International Primary Central Nervous System Lymphoma Collaborative Group Report

被引:158
作者
Cavaliere, Robert [2 ,3 ]
Petroni, Gina [4 ]
Lopes, Maria B. [5 ]
Schiff, David [1 ]
机构
[1] Univ Virginia, Dept Neurol, Div Neurooncol, Charlottesville, VA 22909 USA
[2] Ohio State Univ, Richard J Solove Res Inst, Columbus, OH 43210 USA
[3] Arthur G James Canc Hosp, Columbus, OH USA
[4] Univ Virginia, Dept Biostat & Epidemiol, Charlottesville, VA 22909 USA
[5] Univ Virginia, Dept Pathol, Charlottesville, VA 22909 USA
关键词
post-transplantation lymphoproliferative disorder; lymphoma; central nervous system; rituximab; transplantation; EPSTEIN-BARR-VIRUS; ACTIVE ANTIRETROVIRAL THERAPY; PHASE-II; RITUXIMAB; CNS; TRANSPLANT; SURVIVAL; METHOTREXATE; INVOLVEMENT; EFFICACY;
D O I
10.1002/cncr.24834
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Primary central nervous system (CNS) post-transplantation lymphoproliferative disorder (PCNSPTLD) is a rare complication of solid organ transplantation. The objectives of this study were to define the clinical, radiologic, and pathologic features of this disease and to explore the impact of treatment on patient outcomes. METHODS: The authors reviewed the databases of participating institutions of the International Primary CNS Lymphoma Collaborative Group for cases of PCNS-PTLD. Thirty-four patients who had pathologically confirmed PCNSPTLD without evidence of systemic PTLD were investigated retrospectively. RESULTS: The median time from transplantation to diagnosis of PCNS-PTLD was 4.4 years. Disease usually was multifocal and involved any location of the brain but was most common in the cerebral hemispheres, usually in the subcortical white matter or basal ganglia. Radiographically, all lesions enhanced either homogenously or in a ring-enhancing pattern. Cerebral biopsy was required to establish diagnosis in most patients. Most patients had monomorphic, Epstein-Barr virus (EBV)-positive disease of B-cell origin. Response rates were high regardless of treatment type, and the median survival was 47 months. Age was the only factor predictive of survival. CONCLUSIONS: The current study demonstrated that PCNS-PTLD is typically an EBV-induced B-cell lymphoma that is responsive to treatment with favorable survival in many patients. An aggressive approach to tissue confirmation of diagnosis and treatment with chemotherapy or radiotherapy should be strongly considered. Cancer 2010;116:863-70. (C) 2010 American Cancer Society
引用
收藏
页码:863 / 870
页数:8
相关论文
共 30 条
[1]   Posttransplant lymphoproliferative disorder: Significance of central nervous system involvement [J].
Buell, JF ;
Gross, TG ;
Hanaway, MJ ;
Trofe, J ;
Roy-Chaudhury, P ;
First, MR ;
Woodle, ES .
TRANSPLANTATION PROCEEDINGS, 2005, 37 (02) :954-955
[2]   Post-transplant lymphoproliferative disorders occurring after renal transplantation in adults: Report of 230 cases from the French Registry [J].
Caillard, S. ;
Lelong, C. ;
Pessione, F. ;
Moulin, B. .
AMERICAN JOURNAL OF TRANSPLANTATION, 2006, 6 (11) :2735-2742
[3]   Primary central nervous system posttransplant lymphoproliferative disorders [J].
Castellano-Sanchez, AA ;
Li, SY ;
Qian, J ;
Lagoo, A ;
Weir, E ;
Brat, DJ .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2004, 121 (02) :246-253
[4]   Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders:: results of a prospective multicenter phase 2 study [J].
Choquet, S ;
Leblond, V ;
Herbrecht, R ;
Socié, G ;
Stoppa, AM ;
Vandenberghe, P ;
Fischer, A ;
Morschhauser, F ;
Salles, G ;
Feremans, W ;
Vilmer, E ;
Peraldi, MN ;
Lang, P ;
Lebranchu, Y ;
Oksenhendler, E ;
Garnier, JL ;
Lamy, T ;
Jaccard, A ;
Ferrant, A ;
Offner, F ;
Hermine, O ;
Moreau, A ;
Fafi-Kremer, S ;
Morand, P ;
Chatenoud, L ;
Berriot-Varoqueaux, N ;
Bergougnoux, L ;
Milpied, N .
BLOOD, 2006, 107 (08) :3053-3057
[5]   Palliation of AIDS-related primary lymphoma of the brain: Observations from a multi-institutional database [J].
Corn, BW ;
Donahue, BR ;
Rosenstock, JG ;
Cooper, JS ;
Xie, Y ;
Brandon, AH ;
Hegde, HH ;
Sherr, DL ;
Fisher, SA ;
Berson, A ;
Han, HK ;
Wahab, MA ;
Koprowski, CD ;
Ruffer, JE ;
Curran, WJ .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1997, 38 (03) :601-605
[6]   Highly active antiretroviral therapy is associated with improved survival among patients with AIDS-related primary central nervous system non-Hodgkin's lymphoma [J].
Diamond, Catherine ;
Taylor, Thomas H. ;
Im, Theresa ;
Miradi, Mohammed ;
Wallace, Mark ;
Anton-Culver, Hoda .
CURRENT HIV RESEARCH, 2006, 4 (03) :375-378
[7]   Induction of the Epstein-Barr virus thymidine kinase gene with concomitant nucleoside antivirals as a therapeutic strategy for Epstein-Barr virus-associated malignancies [J].
Faller, DV ;
Mentzer, SJ ;
Perrine, SP .
CURRENT OPINION IN ONCOLOGY, 2001, 13 (05) :360-367
[8]   Prospective phase II trial of extended treatment with rituximab in patients with B-cell post-transplant lymphoproliferative disease [J].
Gonzalez-Barca, Eva ;
Domingo-Domenech, Eva ;
Javier Capote, Francisco ;
Gomez-Codina, Jose ;
Salar, Antonio ;
Bailen, Alicia ;
Ribera, Jose-Maria ;
Lopez, Andres ;
Briones, Javier ;
Munoz, Andres ;
Encuentra, Maite ;
Fernandez de Sevilla, Alberto .
HAEMATOLOGICA, 2007, 92 (11) :1489-1494
[9]  
Harris NL., 2001, PATHOLOGY GENETICS, P264
[10]   Intravenous methotrexate for primary central nervous system non-Hodgkin's lymphoma in AIDS [J].
Jacomet, C ;
Girard, PM ;
Lebrette, MG ;
Farese, VL ;
Monfort, L ;
Rozenbaum, W .
AIDS, 1997, 11 (14) :1725-1730